<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Access Maced J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Open Access Maced J Med Sci</journal-id><journal-title-group><journal-title>Open Access Macedonian Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">1857-9655</issn><publisher><publisher-name>Republic of Macedonia</publisher-name><publisher-loc>ID Design 2012/DOOEL Skopje</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31850114</article-id><article-id pub-id-type="pmc">6910788</article-id><article-id pub-id-type="publisher-id">OAMJMS-7-3018</article-id><article-id pub-id-type="doi">10.3889/oamjms.2019.414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Treatment of Psoriasis: Novel Approaches to Topical Delivery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wollina</surname><given-names>Uwe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Tirant</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Vojvodic</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lotti</surname><given-names>Torello</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Dermatology and Allergology, St&#x000e4;dtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany</aff><aff id="aff2"><label>2</label>Department of Dermatology, University of Rome &#x0201c;G. Marconi&#x0201d;, Rome, Italy</aff><aff id="aff3"><label>3</label>Military Medical Academy of Belgrade, Belgrade, Serbia</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Uwe Wollina. Department of Dermatology and Allergology, St&#x000e4;dtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany. E-mail: <email xlink:href="uwollina@gmail.com">uwollina@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><day>30</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>8</month><year>2019</year></pub-date><volume>7</volume><issue>18</issue><fpage>3018</fpage><lpage>3025</lpage><history><date date-type="received"><day>12</day><month>7</month><year>2019</year></date><date date-type="rev-recd"><day>04</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2019 Uwe Wollina, Michael Tirant, Aleksandra Vojvodic, Torello Lotti.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/CC BY-NC/4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)</license-p></license></permissions><abstract><p>Topical treatment is the cornerstone for the management of mild to moderate psoriasis. Despite efforts in drug development, patient&#x02019;s satisfaction with the available topical treatments is limited. A strategy to improve safety, efficacy and comfort of topical treatment provides the development of new drug delivery and drug carrier systems. This review provides an overview of recent advances in this field with a focus on psoriasis. Laser-assisted drug delivery, foam formulations, nanoparticles, ethosomes, and niomes are considered. Hopefully, these new developments will improve topical drug therapy and patient satisfaction.</p></abstract><kwd-group><kwd>Topical drug therapy</kwd><kwd>Psoriasis</kwd><kwd>Nanoparticles</kwd><kwd>Laser-assisted drug delivery</kwd><kwd>Foams</kwd><kwd>Niosomes</kwd><kwd>Ethosomes</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Easy accessibility of skin is a major factor for topical treatment. Topical drug delivery is depended on skin barrier properties, physicochemical properties of drug and vehicle, and interaction between drug and its vehicle with the skin layers. Penetration into intact skin is usually limited to hydrophilic substances smaller than 500 Da. This explains why highly hydrophilic or highly lipophilic compounds or such compounds with a higher molecular weight are much less suitable for conventional topical drug therapy [<xref rid="ref1" ref-type="bibr">1</xref>].</p><p>Psoriasis is a chronic inflammatory skin disease affecting about 2% of the world population that harms various dimensions of quality of life of patients [<xref rid="ref2" ref-type="bibr">2</xref>]. Topical drug therapy is the cornerstone in the treatment of mild to moderate psoriasis. It offers a direct targeting of affected skin by avoiding systemic adverse events. However, patient satisfaction with available treatments remains modest [<xref rid="ref3" ref-type="bibr">3</xref>].</p><p>There are three major pathways by which drug release into the skin and into the systemic circulation by topical application have to be considered: (a) percutaneous absorption - the passage of topically applied materials into the skin, (b) percutaneous penetration - the passage of material from the stratum corneum surface through the skin to the systemic circulation, and (c) permeation &#x02013; the passage of material through a skin by diffusion or by pores.</p><p>Percutaneous penetration is measured by in vitro skin models such as skin disks, human or animal tissue samples in special skin chambers. Percutaneous penetration measurements are performed in vivo in animal models or humans since they are dependent on blood circulation. Drug concentrations are usually measured by high-performance liquid chromatography (HPLC) or mass spectrometry [<xref rid="ref4" ref-type="bibr">4</xref>]. Proton nuclear magnetic resonance (<xref rid="ref1" ref-type="bibr">1</xref>H NMR) spectroscopy allows the characterisation of the most represented proton-containing low-molecular-mass compounds in a biological sample and their representation in a spectrum [<xref rid="ref5" ref-type="bibr">5</xref>].</p><p>In recent years, several technologies have been developed to enhance the efficacy and safety of topical drug therapy. Furthermore, new drug carriers offer the opportunity to introduce new molecules into topical psoriasis therapy. For these purposes, vesicular drug delivery systems including niosomes, proniosomes, liposomes and transferosomes, nonvesicular drug delivery systems such as foams, gels, and nanoparticles have been developed [<xref rid="ref6" ref-type="bibr">6</xref>]. Hopefully, by using these new technologies, better patient satisfaction with topical treatment could be achieved.</p></sec><sec id="sec1-2"><title>Ablative Fractional Lasers</title><p>Fractional ablative lasers can enhance the permeation of topical drugs into the skin through microscopic ablation zones (MAZs) of precise dimensions. At this moment, the skin barrier can be negotiated, and drug delivery markedly improved [<xref rid="ref7" ref-type="bibr">7</xref>].</p><p>Several studies investigated topical methotrexate. Methotrexate is a folic acid analogue. The mechanism of action is the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase, thus increasing intracellular and extracellular adenosine which has anti-inflammatory activity. Methotrexate has been used for a long time in the systemic treatment of both psoriasis and psoriasis arthritis. In contrast to its use in oncology, methotrexate is used just once a week in low dosages (usually 7.5-25 mg) orally, subcutaneously or intravenously in both indications [<xref rid="ref8" ref-type="bibr">8</xref>]. Systemic treatment, however, is limited by possible methotrexate toxicities [<xref rid="ref9" ref-type="bibr">9</xref>].</p><p>A systematic in vitro study with a low-power 2,940 nm ablative fractional erbium YAG laser investigated the correlation between laser parameters and tissue. Deeper MAZ depth increased the concentration of methotrexate in the deeper tissue layer. The biodistribution of the drug was surprisingly not compromised by coagulation zones of various thickness around MAZ. The ratio of skin deposition versus transdermal permeation was constant, not depending on the MAZ depth. Methotrexate distributed radially from the MAZ. Saturation of the skin occurred after 7 hours at a ten-fold concentration compared to intact skin [<xref rid="ref10" ref-type="bibr">10</xref>].</p><p>The same technique can be applied to the treatment of nail psoriasis [<xref rid="ref11" ref-type="bibr">11</xref>].</p><p>In a clinical trial using nanoparticulated methotrexate in jojoba oil-based microemulsion, fractional erbium YAG laser resulted in a faster clinical response compared to intact skin, i.e. 3 weeks vs 8 weeks [<xref rid="ref12" ref-type="bibr">12</xref>].</p></sec><sec id="sec1-3"><title>Foams</title><p>Foams are colloids composed of two or three distinct phases: hydrophilic liquid continuous phase with a foaming agent, throughout which a gaseous dispersion phase is distributed, and sometimes a third hydrophobic dispersed phase. Pharmaceutical aerosol foams commonly exhibit three transition states: liquid in the can, propellant/aerosol as it leaves the can and foam on the skin of the patient [<xref rid="ref13" ref-type="bibr">13</xref>].</p><p>A fixed combination of calipotriol and betametasone dipropionate is on the market and found to superior to betamethasone ointment [<xref rid="ref14" ref-type="bibr">14</xref>]. Betamethasone dipropionate in micronised particles can be easily suspended homogeneously. Calcipotriol, on the other hand, is a greater challenge and needs to be dissolved in a carefully selected vehicle component to ensure even distribution. The product contains an emollient vehicle base, with calcipotriol and betamethasone dissolved in a mixture of volatile propellants, butane and dimethyl ether. Dimethyl ether also acts as a solvent that enhances the solubility of the active ingredients allowing them to dissolve completely. It has been demonstrated that this anti-psoriatic foam formulation is more effective at week 12 than systemic methotrexate or acitretin, and it is more effective at week 16 as systemic apremilast measured by the PASI75 response [<xref rid="ref15" ref-type="bibr">15</xref>].</p></sec><sec id="sec1-4"><title>Nanofibres</title><p>Curcumin is a herbal substance with anti-inflammatory activities, that is of interest also in topical psoriasis therapy [<xref rid="ref16" ref-type="bibr">16</xref>]. Cellulose nanofiber (CNF) is a biocompatible biomaterial with film-forming properties and excellent mechanical properties. Fibres of a diameter of approximately 500 nm were embedded in a composition containing shea butter and Capmul MCM EP and loaded with curcumin (liquid@CNF). They employed a variety of analytical methods including scanning and transmission electron microscopy, Fourier transform infrared spectroscopy, also known as FTIR analysis. The FTIR analysis method uses infrared light to scan test samples and observe chemical properties. X-ray photoelectron spectroscopy was used to analyse the surface chemistry of the curcumin preparation. Besides, atomic force microscopy was used to measure the local properties of curcumin-CSF. In a mouse model with imiquimod-induced psoriasis-like dermatitis, deposition of curcumin was increased 2-fold compared with films missing the lipid component. Curcumin-CNF improved dermatitis in vivo including a reduction of pro-inflammatory cytokines in a range close to commercially available topical corticosteroids. Furthermore, the films had a skin hydration effect [<xref rid="ref17" ref-type="bibr">17</xref>].</p></sec><sec id="sec1-5"><title>Nanoparticles and Nano Emulsions</title><p>Another option to overcome skin barrier is the use of nanoparticles, especially for hydrophilic compounds. The most commonly used nanoparticles for topical drug delivery are polymeric nanoparticles, nano-emulsions, liposomes and solid lipid nanoparticles, metal nanoparticles, and dendrimers. Nanoparticles are used to enhance the solubility of highly hydrophobic drugs. They provide a sustained and controlled release of drugs while increasing their stability. Nanoparticles are capable of delivering higher concentrations of drugs to target areas. Nanoparticles can accumulate in hair follicles and thereby overcome the skin barrier [<xref rid="ref18" ref-type="bibr">18</xref>].</p><p>Curcumin-loaded nanoparticles (NPs) made of poly (lactic-co-glycolic acid) with a mean particle size of 50 nm and 150 nm. In vitro, these NPs exerted a stronger anti-proliferative activity of human HaCaT keratinocytes than curcumin alone. Psoriatic skin samples were used for in vitro penetration studies. Curcumin-loaded NPs delivered more curcumin into the skin than curcumin hydrogel. Curcumin-loaded NPs was investigated in vivo in the imiquimod-induced mouse model versus tacrolimus cream. Clinical symptoms, histology and inflammatory cytokines improved most with curcumin-loaded NPs with 50 nm NPs reaching the most pronounced effects [<xref rid="ref19" ref-type="bibr">19</xref>].</p><p>An amphiphilic polymer, RRR-&#x003b1;-tocopheryl succinate-grafted-&#x003b5;-polylysine conjugate (VES-g-&#x003b5;-PLL), was synthesised and self-assembled into skin penetrating polymeric NPs with a hydrodynamic diameter of only 24.4 nm. In these NPs curcumin could effectively be encapsulated with a drug loading capacity of 3.49% and an encapsulating efficiency of 78.45%. Silk fibroin was used as a hydrogel-based matrix to enhance further topical delivery of curcumin-NPs, which resulted in a slower release. In vivo studies on imiquimod-induced psoriasis-like dermatitis in mice, curcumin-NPs-silk fibroin gel demonstrated a high skin-permeating capability and a stronger anti-inflammatory activity. This was investigated by inhibitory effects on the expression of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNFa), nuclear factor-&#x003ba;B and interleukin-6) [<xref rid="ref20" ref-type="bibr">20</xref>].</p><p>Bacterial cellulose (BC) represents an interesting biocompatible nanomaterial. BC can be easily manipulated to improve its properties and/or functionalities resulting in several BC-based nanocomposites such as BC/collagen, BC/gelatin, BC/fibroin, BC/chitosan. Bacterial cellulose/carboxymethylcellulose (BC / CMC) biocomposite nanofibers can also serve as drug carriers. This was investigated using methotrexate, a conventional systemic antipsoriatic drug with anti-folate activity. Biocomposites loaded with methotrexate may be used as an alternative for the topical treatment of psoriasis. There was a decrease in the elastic modulus as the degree of substitution of CMC increased. Intermediate substitute CMC grade led to a slightly decreased MTX release rate, suggesting that the degree of substitution of CMC is a key factor to modulate the biocomposite properties [<xref rid="ref21" ref-type="bibr">21</xref>].</p><p>Spherical methotrexate-loaded chitin nanogel (MCNG) with a particle size of 196 nm was formulated for topical use in psoriasis. Exposure of HaCaT keratinocytes and THP-1 cells to MCNG showed a significant level of cellular toxicity. MCNGs inhibited COX-2 and LOX-5 enzymes expressed in THP-1 cells. Skin permeation studies revealed an increased transdermal flux of methotrexate from MCNG in comparison with methotrexate solution treated samples. Furthermore, it could be shown that MCNG exerted anti-psoriatic efficacy on an imiquimod-induced mouse model of psoriasis. No dermal and systemic toxicities were reported [<xref rid="ref22" ref-type="bibr">22</xref>].</p><p>Pentoxifylline (PTX) is an anti-inflammatory activity compound and exerts inhibitory activity against TNFa, one of the major proinflammatory cytokines involved in psoriasis. Therefore, it is of potential interest in topical psoriasis therapy &#x02014; colloidal nanostructured lipid carriers (NLCs) with a size of less than 200 nm. PTX was loaded and encapsulated to the extent of 10% and 90% in the NLCs. In vitro studies suggested high retention of PTX in the skin (84%). In vivo, imiquimod-induced psoriasis in the mouse model was employed. PTX-loaded NCLs demonstrated a significant improvement of histological changes in the affected epidermis [<xref rid="ref23" ref-type="bibr">23</xref>].</p><p>In contrast to PTX, topical corticosteroids are established drugs in psoriasis therapy. They are the cornerstone of topical outpatient treatment worldwide. Mometasone furoate-loaded NLCs with a droplet size of approximately 160 nm, a zeta potential-0.086 mV and entrapment efficiency of 60.0 % were transformed into a hydrogel using Carbopol 940 to optimise viscosity for topical use. Drug permeation studies showed prolonged drug release as compared to commercial mometasone formulation. The mometasone skin concentration was 2.5-fold higher than commercial corticosteroids. In vivo studies in imiquimod induced skin inflammation in Wistar rats demonstrated the absence of parakeratosis in mometasone-loaded NLC treated lesions [<xref rid="ref24" ref-type="bibr">24</xref>].</p><p>Nanogels are water-soluble cross-linked polymer networks with nanometer-size dimensions. They can be designed to incorporate different types of anti-psoriatic compounds and are promising carrier systems for topical drug delivery. Gels produced with macromolecules and fibres can be classified as polymers with molecules attached to the fibres throughout the gel resulting in a polymer (chemical gel) or supramolecular gels (physical gels), in which smaller molecules are attached van der Waals interactions, hydrogen bonds or coulombic forces [<xref rid="ref25" ref-type="bibr">25</xref>]. While chemical gels are robust materials, physical gels are more suitable for drug delivery. These gels are also softer. While most physical gels are made by polymeric subunits, low-molecular-weight gelators (LMWGs) are smaller molecules that self-assemble to form fibres. Such gels have qualities that made them interesting for drug delivery, such as thermoreversibility and degradability [<xref rid="ref26" ref-type="bibr">26</xref>].</p><p>Bis-imidazolium (1&#x022c5;2 Br) salts are cationic surfactants that could form micelles and deliver anionic drugs. The electrostatic attraction between the positively charged surfactant and the negatively charged drug is responsible for a slow but sustained release of the drug [<xref rid="ref27" ref-type="bibr">27</xref>]. Triamcinolone acetonide and betamethasone 17-valerate are commonly used topical corticosteroid for inflammatory skin disorders such as psoriasis. The 1&#x022c5;2 Br carrier material permitted a high level of drug release and did not limit permeation of the drug into human skin as measured by Franz cells. Gels derived from 1&#x022c5;2 Br released up to three times more triamcinolone or betamethasone than two commercial products, which served as controls. Also, the speed of drug release was ten times faster if they were incorporated in gel 1&#x022c5;2 Br. Permeation studies using Franz cells show that gel 1&#x022c5;2 Br promotes the entry of the drug through the skin four times more rapidly than the commercial formulations. The gel also promotes retention of the drug in the skin two times (betamethasone) and 20-fold (triamcinolone) more than the commercial formulations. In conclusion, 1&#x022c5;2 Br carrier material ensures a faster action and higher bioavailability to the pharmacological target [<xref rid="ref28" ref-type="bibr">28</xref>].</p><p>Further investigations demonstrated that several other possible compounds for topical psoriasis therapy could also be included and stabilised in nanostructures supramolecular gels such as methotrexate or tacrolimus [<xref rid="ref29" ref-type="bibr">29</xref>].</p><p>PUVA-therapy &#x02013; 8-methoxy psoralen (8MOP) plus ultraviolet A irradiation &#x02013; is an established treatment for psoriasis, vitiligo and cutaneous T-cell lymphoma amongst other dermatoses [<xref rid="ref30" ref-type="bibr">30</xref>].</p><p>8MOP has been incorporated into a nanoemulsion (NE) that showed a mean droplet diameter of 24.98&#x000b1; 0.49 nm, polydispersity index of 0.091 &#x000b1; 0.23, pH values of 6.54 &#x000b1; 0.06, the refractive index of 1.3525 &#x000b1; 0.0001, and apparent viscosity of 51.15 &#x000b1; 3.66 mPa at 20&#x000b0;C. The formulation was characterised by ex vivo permeation study using porcine skin with fluorescence HPLC and transmission electron microscopy, to determine the amount of drug retained in stratum corneum, viable epidermis, and dermis. Ex vivo permeation revealed that 8.5% of the applied 8MOP dose permeated through the biological membranes, with a flux of 1.35 &#x003bc;g cm<sup>-2</sup> h<sup>-1</sup>. The drug retention in viable epidermis and dermis was twice as high as normal cream with 10.15 &#x000b1; 1.36 &#x000b5;g cm<sup>-2</sup> compared to stratum corneum with 1.95 &#x000b1; 0.71 &#x000b5;g cm<sup>-2</sup>, respectively [<xref rid="ref31" ref-type="bibr">31</xref>].</p><p>Since NE may have a relatively low viscosity, hydrogel-thickened NEs using chitosan have been prepared to improve topical applicability. The size of chitosan molecules influences drug release [<xref rid="ref32" ref-type="bibr">32</xref>].</p><p>Cignolin (syn. dithranol or anthralin) is the most potent topical drug in psoriasis therapy with the longest remission times [<xref rid="ref33" ref-type="bibr">33</xref>]. However, skin irritation and staining hamper its broader use. Microspongues as delivery systems for cignolin may overcome these problems. In one study, microsponges were composed of poly (amido) amine dendrimers, ethylcellulose, polyvinyl alcohol, dichloromethane, sodium metabisulphate, and distilled water. In vitro studies demonstrated that such a formulation could prevent autooxidation of cignolin. Microsponge gel of dithranol may provide further advantages of reduced side effects, increased elegance, enhanced formulation flexibility, and modified drug release [<xref rid="ref34" ref-type="bibr">34</xref>].</p><p>Cignolin has also been used with NLCs for better application and efficacy. Cignolin-loaded NLCs were prepared by hot-melt homogenization with particle size &#x0003c; 300 nm, polydispersity index (PDI) &#x0003c; 0.3 and percentage entrapment efficiency of &#x0223c;100%. The NLCs were loaded into a gel and evaluated for drug release, spreadability, rheological behaviour, and staining. Anti-psoriatic efficacy was evaluated in the imiquimod-induced psoriatic plaque model in comparison with conventional 1.15% w/w cignolin ointment. Topical application of cignolin-loaded NLC gel reduced the PASI score. There was a significant reduction in IL-17, 22, 23 and TNFa as measured by enzyme-linked immunosorbent assays [<xref rid="ref35" ref-type="bibr">35</xref>].</p><p>Cyclosporine A (CsA) is a calcineurin inhibitor which acts on T-cells and is an effective systemic treatment for psoriasis. However, systemic administration of CsA can cause dose-dependent toxic effects, which may be circumvented by topical drug delivery. Topical use, however, is hindered by its high molecular weight of 1,202 Da [<xref rid="ref36" ref-type="bibr">36</xref>].</p><p>Recently a topical liposomal gel containing CsA loaded cationic liposomal nanocarriers has been developed. Optimised liposomal carriers prepared by the ethanol injection method were loaded with CsA and applied in a gel formulation on imiquimod-induced plaque model. Thereby, clinical symptoms could be improved, and key pro-inflammatory cytokines for psoriasis such as tumour necrosis factor-&#x003b1;, IL-17, and IL-22 were reduced [<xref rid="ref37" ref-type="bibr">37</xref>].</p><p>A CsA-loaded microemulsions using oleic acid as oil phase, either Tween&#x000ae;80 or a soluble derivative of vitamin E (TPGS) as surfactants and either Transcutol&#x000ae;, propylene glycol or 1,3 propanediol as co-surfactants. Several Tween&#x000ae;80-based and 4 TPGS-based formulations were tested ex vivo, loaded with 6 mg/g CsA and applied ex-vivo on porcine skin for 22 h. A 3- or 6-fold higher cutaneous accumulation compared with CsA in propylene glycol could be obtained by a low-viscosity Tween&#x000ae;80-based microemulsion (9.78 &#x000b1; 3.86 &#x000b5;g cm<sup>-2</sup>) and with a high viscosity TPGS-based microemulsion (18.3 &#x000b1; 5.69 &#x000b5;g cm<sup>-2</sup>), respectively. The uptake of CsA by porcine skin was noted as early as two hours after application [<xref rid="ref38" ref-type="bibr">38</xref>].</p><p>Another study investigated CsA-loaded polymeric micelles using the biodegradable and biocompatible MPEG-dihexPLA diblock copolymer. These polymeric micelles deliver CsA without penetrating the skin. They increased the aqueous solubility of CsA by 518-fold. Supra-therapeutic amounts of CsA were delivered to human skin (1.4 &#x000b1; 0.6 &#x003bc;g cm<sup>-2</sup>) after application of the formulation with 1.67 mg/ml CsA and 5 mg/ml copolymer for the only 1h without transdermal permeation. The micelles were preferentially deposited between corneocytes and in between the clusters of corneocytes [<xref rid="ref39" ref-type="bibr">39</xref>].</p><p>Tacrolimus is a specific calcineurin inhibitor approved or atopic dermatitis and with moderate antipsoriatic activity for intertriginous psoriasis [<xref rid="ref40" ref-type="bibr">40</xref>]. It suffers from poor cutaneous bioavailability when administered topically as protopic ointment. Therefore, polymeric micelles using methoxy-poly (ethylene glycol)-dihexyl substituted polylactide (MPEG-dihexPLA) diblock copolymer loaded with 0.1% tacrolimus was investigated in vitro. Delivery experiments using human skin resulted in significantly greater tacrolimus deposition compared to protopic 0.1% ointment, i.e. 1.50 &#x000b1; 0.59 versus 0.47 &#x000b1; 0.20 &#x003bc;g cm<sup>-2</sup>). The increase in cutaneous drug concentrations was due to improved drug load of stratum corneum, viable epidermis, and upper dermis, while the copolymer was unable to penetrate the stratum corneum. Preferential deposition of tacrolimus-loaded micelles into the hair follicle was also documented [<xref rid="ref41" ref-type="bibr">41</xref>].</p><p>Another study investigated a hybrid system based on nicotinamide (NIC) and nanoparticles (NPs) encapsulating tacrolimus to improve percutaneous drug delivery. NIC increased both the solubility and permeability of tacrolimus. NIC demonstrated self-assembly with amphiphilic hyaluronic acid-cholesterol conjugates. Thee NPs showed a higher encapsulation efficiency of 79.2% &#x000b1; 4.2%, and the combination of NPs with NIC exhibited a significant synergistic effect on tacrolimus absorption within the skin (2.39 &#x000b1; 0.53 &#x003bc;g cm<sup>-2</sup>) and penetration through the skin (13.38 &#x000b1; 2.26 &#x003bc;g cm<sup>-2</sup>) as measured by confocal laser scanning microscopy. The cellular uptake of tacrolimus in HaCaT cells was also improved by NPs [<xref rid="ref42" ref-type="bibr">42</xref>].</p><p>One trial investigated the applicability of NIC-based hybrid systems with chitosan instead of hyaluronic acid on tacrolimus efficacy in an animal model of atopic dermatitis (AD). AD-like skin lesions were induced by 1-chloro-2, 4-dinitrobenzene (DNCB) in BALB/c mice. In vitro and in vivo skin permeation studies demonstrated that this NIC-chitosan-NPs system significantly enhanced tacrolimus cutaneous permeation and penetration compared to commercial tacrolimus ointment. The treatment efficacy on clinical symptoms, histological analysis, and molecular biology of the AD-mice demonstrated that NIC-chitosan-NPs were more potent than the commercial ointment while using only one-third of their dosage [<xref rid="ref43" ref-type="bibr">43</xref>]. The anti-TNFa fusion protein etanercept (molecular weight 150 kDa) is an effective drug in the systemic treatment of moderate to severe psoriasis. Due to the high molecular weight, the compound cannot penetrate human skin [<xref rid="ref44" ref-type="bibr">44</xref>].</p><p>Recently, etanercept was successfully and stable encapsulated in thermoresponsive nanogels (tNG). Topical application of etanercept-loaded tNGs to human skin equivalents, prepared from primary human keratinocytes and fibroblasts and treated with TNFa, or tape striped human skin resulted in inefficient drug delivery throughout the stratum corneum and into the viable epidermis. Effective etanercept delivery was depended on temperature triggered release following topical application. Anti-inflammatory activity on TNFa, intercellular adhesion molecule 1, and thymic stromal lymphopoietin was measured by immunochemistry, enzyme-linked immunoassays, and Western blots. It was shown that the formulation was non-toxic for monocyte-derived Langerhans cells [<xref rid="ref45" ref-type="bibr">45</xref>].</p><p>In another study, two different tNGs were synthesized, i.e. tNG_dPG_tPG-a combination of dendritic polyglycerol with poly (glycidyl methyl ether-co-ethyl glycidyl ether) (p(GME-co-EGE)) and tNG_dPG_pNIPAM with poly(N-isopropylacrylamide). These tNGs were capable of incorporating high amounts of the corticosteroid dexamethasone and tacrolimus. Cellular uptake and intracellular localisation were investigated in cell cultures of normal human keratinocytes and HaCaT cells. Neither cytotoxic nor genotoxic effects were noted. There was no induction of reactive oxygen species in keratinocytes. tNGs with a thermally triggered release at 35&#x000b0;C seem to be optimal for topical application on human skin [<xref rid="ref46" ref-type="bibr">46</xref>].</p></sec><sec id="sec1-6"><title>Ethosomes</title><p>Ethosomes are flexible nanovesicles composed of multiple, concentric layers of flexible phospholipid bylayers, with 20 to 45% of ethanol, glycol and water. They are used for dermal and transdermal delivery of molecules since they can penetrate the stratum corneum [<xref rid="ref47" ref-type="bibr">47</xref>].</p><p>However, percutaneous absorption and penetration of lipophilic 8MOP in intact skin are poor. After the development of microemulsions about 20 years ago, more recently nanocarriers were investigated for improved drug supply of 8MOP. In vitro skin permeation demonstrated a permeability of psoralen-loaded ethosomes superior to that of liposomes. With psoralen-loaded ethosomes, transdermal flux and skin deposition could be increased 3.50 and 2.15 times compared to psoralen-loaded liposomes [<xref rid="ref48" ref-type="bibr">48</xref>].</p><p>One trial used spherical and multilamellar ethosomes incorporated into Carbopol&#x000ae; 934 gel. They were characterized for drug content, rheological behaviour, texture profile, in vitro release, ex vivo skin permeation and retention, skin photosensitization and histopathological examination. Ethosomal formulations showed significant skin permeation and accumulation in the epidermal and dermal layers as demonstrated by fluorescence microscopy study using <sup>123</sup>rhodamine while phototoxicity was not enhanced [<xref rid="ref49" ref-type="bibr">49</xref>].</p></sec><sec id="sec1-7"><title>Niosomes</title><p>Niosomes represent non-ionic surfactant-based vesicles formed mostly by non-ionic surfactant and cholesterol. They can entrap lipophilic drugs into vesicular bilayer membranes and hydrophilic drugs. Niosomes are osmotically active [<xref rid="ref50" ref-type="bibr">50</xref>].</p><p>Acitretin is a vitamin-A analogue with antipsoriatic and anti-inflammatory activities. Systemic acitretin therapy warrants a close laboratory monitoring to prevent severe adverse events. Niosomes of approximately 370 nm were loaded with acitretin. Acitretin nanosized niosomal gel offered an enhanced ex vivo permeation profile drug deposition in the viable skin layers compared with acitretin gel. Acitretin-loaded nano-niosomes demonstrated an increased antiproliferative activity in HaCaT cell culture. Topical application of acitretin nano-niosomal gel to a mouse tail model achieved a significantly higher amount of orthokeratosis, drug activity, and reduction in epidermal thickness compared with controls. The formulation was characterised by improved tolerability and much less skin irritation [<xref rid="ref51" ref-type="bibr">51</xref>].</p><p>Niosome technology has also been investigated for PUVA therapy with 8MOP. 8MOP niosomes were prepared by the thin-film hydration method along with cholesterol demonstrated a high entrapment efficiency (83-90%) with vesicle diameters between 111.1 and 198.8 nm. Physical stability over 6 months at different temperatures was good. Niosome formulations were incorporated in 5% sodium carboxy methylcellulose-hydrogel matrix which showed a more retarded 8MOP release compared to niosomal vesicles. The skin penetration of the niosomes was studies in vivo by confocal laser scanning microscopy using <sup>123</sup>rhodamine-loaded niosomal hydrogels compared to plain <sup>123</sup>rhodamine hydrogel. In vitro drug permeation and deposition studies with rat skin demonstrated improved penetration and accumulation of 8MOP after 8h [<xref rid="ref52" ref-type="bibr">52</xref>].</p><p>Proniosomes are liquid crystalline compact niosome hybrids which upon hydration form niosomes. They support physical stability such as leaking, fusion, aggregation and provide convenience in dosing, distribution, transportation and storage. Therefore, proniosomes seem to be superior to conventional niosomes [<xref rid="ref53" ref-type="bibr">53</xref>].</p><p>A non-ionic surfactant based proniosomal gel (PNG) was developed to improve topical delivery of tazarotene &#x02013; a retinoid for psoriasis. The PNG was had a vesicle size of 3.26 &#x003bc;m. Different formulations were investigated for drug release through cellulose membrane and rat skin, which showed a prolonged release of entrapped tazarotene. The formulations varied in drug permeation and retention in vitro. The male Albino NMRI mice tail model was used for in vivo studies. Span 60 based PNG formulations were able to increase drug accumulation in skin and reduce parakeratosis in the horny layer [<xref rid="ref54" ref-type="bibr">54</xref>].</p></sec><sec sec-type="conclusions" id="sec1-8"><title>Conclusions</title><p>Topical drug delivery is a field of recent research with great clinical implications. In contrast to the development of targeted systemic treatments and biologics, improved topical drug delivery is focused on the great majority of psoriasis patients with mild to moderate disease. Various anti-inflammatory drugs and herbal compounds are under investigation. Hopefully, a number these topical treatments become available for the dermatologic practice.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Funding:</bold> This research did not receive any financial support</p></fn><fn fn-type="other"><p><bold>Competing Interests:</bold> The authors have declared that no competing interests exist</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>YB</given-names></name><name><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group><article-title>The rule of five for non-oral routes of drug delivery:ophthalmic, inhalation and transdermal</article-title><source>Pharm Res</source><year>2011</year><volume>28</volume><issue>5</issue><fpage>943</fpage><lpage>8</lpage><comment>https://doi.org/10.1007/s11095-010-0292-6</comment><comment>PMid:20967491 PMCid:PMC3074025</comment><pub-id pub-id-type="pmid">20967491</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wollina</surname><given-names>U</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fran&#x000e7;a</surname><given-names>K</given-names></name><name><surname>Lotti</surname><given-names>T</given-names></name></person-group><article-title>Psoriasis</article-title><source>Advances in Integrative Dermatology</source><volume>2019</volume><edition>1st Edition</edition><publisher-loc>Chichester, UK</publisher-loc><publisher-name>John Wiley &#x00026;Sons, Ltd</publisher-name><fpage>131</fpage><lpage>144</lpage><comment>https://doi.org/10.1002/9781119476009.ch10</comment></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florek</surname><given-names>AG</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Armstrong</surname><given-names>AW</given-names></name></person-group><article-title>Treatment preferences and treatment satisfaction among psoriasis patients:a systematic review</article-title><source>Arch Dermatol Res</source><year>2018</year><volume>310</volume><issue>4</issue><fpage>271</fpage><lpage>319</lpage><comment>https://doi.org/10.1007/s00403-018-1808-x</comment><comment>PMid:29442137</comment><pub-id pub-id-type="pmid">29442137</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Telekes</surname><given-names>A</given-names></name><name><surname>Heged&#x00171;s</surname><given-names>M</given-names></name><name><surname>Kiss</surname><given-names>I</given-names></name></person-group><person-group person-group-type="editor"><name><surname>V&#x000e9;key</surname><given-names>K</given-names></name><name><surname>Telekes</surname><given-names>A</given-names></name><name><surname>Vertes</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic drug monitoring and measurement of drug concentrations using mass spectrometry</article-title><source>Medical Applications of Mass Spectrometry</source><volume>2008</volume><publisher-name>Elsevier</publisher-name><fpage>263</fpage><lpage>89</lpage><comment>https://doi.org/10.1016/B978-044451980-1.50015-X</comment></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurie</surname><given-names>DJ</given-names></name><name><surname>M&#x000e4;der</surname><given-names>K</given-names></name></person-group><article-title>Monitoring drug delivery processes by EPR and related techniques--principles and applications</article-title><source>Adv Drug Deliv Rev</source><year>2005</year><volume>57</volume><issue>8</issue><fpage>1171</fpage><lpage>90</lpage><comment>https://doi.org/10.1016/j.addr.2005.01.023</comment><comment>PMid:15935868</comment><pub-id pub-id-type="pmid">15935868</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamishehkar</surname><given-names>H</given-names></name><name><surname>Rahimpour</surname><given-names>Y</given-names></name><name><surname>Kouhsoltani</surname><given-names>M</given-names></name></person-group><article-title>Niosomes as a propitious carrier for topical drug delivery</article-title><source>Expert Opin Drug Deliv</source><year>2013</year><volume>10</volume><issue>2</issue><fpage>261</fpage><lpage>72</lpage><comment>https://doi.org/10.1517/17425247.2013.746310</comment><comment>PMid:23252629</comment><pub-id pub-id-type="pmid">23252629</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>CY</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Alalaiwe</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name></person-group><article-title>Laser ablation and topical drug delivery:a review of recent advances</article-title><source>Expert Opin Drug Deliv</source><volume>2019</volume><fpage>1</fpage><lpage>16</lpage><comment>https://doi.org/10.1080/17425247.2019.1649655</comment><comment>PMid:31389261</comment></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangert</surname><given-names>CA</given-names></name><name><surname>Costner</surname><given-names>MI</given-names></name></person-group><article-title>Methotrexate in dermatology</article-title><source>Dermatol Ther</source><year>2007</year><volume>20</volume><issue>4</issue><fpage>216</fpage><lpage>28</lpage><comment>https://doi.org/10.1111/j.1529-8019.2007.00135.x</comment><comment>PMid:17970887</comment><pub-id pub-id-type="pmid">17970887</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollina</surname><given-names>U</given-names></name><name><surname>St&#x000e4;nder</surname><given-names>K</given-names></name><name><surname>Barta</surname><given-names>U</given-names></name></person-group><article-title>Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients</article-title><source>Clin Rheumatol</source><year>2001</year><volume>20</volume><issue>6</issue><fpage>406</fpage><lpage>10</lpage><comment>https://doi.org/10.1007/s100670170004</comment><comment>PMid:11771523</comment><pub-id pub-id-type="pmid">11771523</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taudorf</surname><given-names>EH</given-names></name></person-group><article-title>Laser-assisted delivery of topical methotrexate - in vitro investigations</article-title><source>Dan Med J</source><year>2016</year><volume>63</volume><issue>6</issue></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HX</given-names></name><name><surname>Banga</surname><given-names>AK</given-names></name></person-group><article-title>Effect of ablative laser on in vitro transungual delivery</article-title><source>Int J Pharm</source><year>2018</year><volume>544</volume><issue>2</issue><fpage>402</fpage><lpage>414</lpage><comment>https://doi.org/10.1016/j.ijpharm.2017.09.048</comment><comment>PMid:28951347</comment><pub-id pub-id-type="pmid">28951347</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramez</surname><given-names>SA</given-names></name><name><surname>Soliman</surname><given-names>MM</given-names></name><name><surname>Fadel</surname><given-names>M</given-names></name><name><surname>Nour El-Deen</surname><given-names>F</given-names></name><name><surname>Nasr</surname><given-names>M</given-names></name><name><surname>Youness</surname><given-names>ER</given-names></name><name><surname>Aboel-Fadl</surname><given-names>DM</given-names></name></person-group><article-title>Novel methotrexate soft nanocarrier/fractional erbium YAG laser combination for clinical treatment of plaque psoriasis</article-title><source>Artif Cells Nanomed Biotechnol</source><year>2018</year><volume>46</volume><issue>sup1</issue><fpage>996</fpage><lpage>1002</lpage><comment>https://doi.org/10.1080/21691401.2018.1440236</comment><comment>PMid:29448838</comment><pub-id pub-id-type="pmid">29448838</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tamarkin</surname><given-names>D</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Dayan</surname><given-names>N</given-names></name></person-group><article-title>Chapter 9 Foam:a unique delivery vehicle for topically applied formulations</article-title><source>Handbook of formulating dermal applications:a definitive practical guide</source><volume>2017</volume><publisher-loc>Beverly, MA</publisher-loc><publisher-name>Scrivener Publishing</publisher-name><fpage>233</fpage><lpage>60</lpage><comment>https://doi.org/10.1002/9781119364221.ch9</comment></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>LS</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Villumsen</surname><given-names>J</given-names></name><name><surname>Rosen</surname><given-names>M</given-names></name><name><surname>Koo</surname><given-names>J</given-names></name></person-group><article-title>Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris:Pooled Data From Three Randomized Controlled Studies</article-title><source>J Drugs Dermatol</source><year>2016</year><volume>15</volume><issue>8</issue><fpage>951</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">27537995</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bewley</surname><given-names>AP</given-names></name><name><surname>Shear</surname><given-names>NH</given-names></name><name><surname>Calzavara-Pinton</surname><given-names>PG</given-names></name><name><surname>Hansen</surname><given-names>JB</given-names></name><name><surname>Nyeland</surname><given-names>ME</given-names></name><name><surname>Signorovitch</surname><given-names>J</given-names></name></person-group><article-title>Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis:a matching-adjusted indirect comparison</article-title><source>J Eur Acad Dermatol Venereol</source><year>2019</year><volume>33</volume><issue>6</issue><fpage>1107</fpage><lpage>15</lpage><comment>https://doi.org/10.1111/jdv.15369</comment><comment>PMid:30472749 PMCid:PMC6766948</comment><pub-id pub-id-type="pmid">30472749</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardo</surname><given-names>VD</given-names></name><name><surname>Gianfaldoni</surname><given-names>S</given-names></name><name><surname>Tchernev</surname><given-names>G</given-names></name><name><surname>Wollina</surname><given-names>U</given-names></name><name><surname>Barygina</surname><given-names>V</given-names></name><name><surname>Lotti</surname><given-names>J</given-names></name><name><surname>Daaboul</surname><given-names>F</given-names></name><name><surname>Lotti</surname><given-names>T</given-names></name></person-group><article-title>Use of Curcumin in Psoriasis</article-title><source>Open Access Maced J Med Sci</source><year>2018</year><volume>6</volume><issue>1</issue><fpage>218</fpage><lpage>20</lpage><comment>https://doi.org/10.3889/oamjms.2018.055</comment><comment>PMid:29484027 PMCid:PMC5816303</comment><pub-id pub-id-type="pmid">29484027</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>NW</given-names></name><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Sohn</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>KT</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>DD</given-names></name></person-group><article-title>Curcumin-loaded lipid-hybridized cellulose nanofiber film ameliorates imiquimod-induced psoriasis-like dermatitis in mice</article-title><source>Biomaterials</source><year>2018</year><volume>182</volume><fpage>245</fpage><lpage>58</lpage><comment>https://doi.org/10.1016/j.biomaterials.2018.08.030</comment><comment>PMid:30142524</comment><pub-id pub-id-type="pmid">30142524</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>R</given-names></name><name><surname>Macri</surname><given-names>LK</given-names></name><name><surname>Kaplan</surname><given-names>HM</given-names></name><name><surname>Kohn</surname><given-names>J</given-names></name></person-group><article-title>Nanoparticles and nanofibers for topical drug delivery</article-title><source>J Control Release</source><year>2016</year><volume>240</volume><fpage>77</fpage><lpage>92</lpage><comment>https://doi.org/10.1016/j.jconrel.2015.10.049</comment><comment>PMid:26518723 PMCid:PMC4896846</comment><pub-id pub-id-type="pmid">26518723</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangeetha</surname><given-names>NM</given-names></name><name><surname>Maitra</surname><given-names>U</given-names></name></person-group><article-title>Supramolecular gels:functions and uses</article-title><source>Chem Soc Rev</source><year>2005</year><volume>34</volume><issue>10</issue><fpage>821</fpage><lpage>36</lpage><comment>https://doi.org/10.1039/b417081b PMid:16172672</comment><pub-id pub-id-type="pmid">16172672</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cun</surname><given-names>D</given-names></name><name><surname>Tong</surname><given-names>HHY</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name></person-group><article-title>Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel</article-title><source>J Control Release</source><year>2017</year><volume>254</volume><fpage>44</fpage><lpage>54</lpage><comment>https://doi.org/10.1016/j.jconrel.2017.03.385</comment><comment>PMid:28344018</comment><pub-id pub-id-type="pmid">28344018</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>KL</given-names></name><name><surname>Fan</surname><given-names>ZL</given-names></name><name><surname>Yuan</surname><given-names>JD</given-names></name><name><surname>Chen</surname><given-names>PP</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>ZhuGe</surname><given-names>DL</given-names></name><name><surname>Jin</surname><given-names>BH</given-names></name><name><surname>Zhu</surname><given-names>QY</given-names></name><name><surname>Shen</surname><given-names>BX</given-names></name><name><surname>Sohawon</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>YZ</given-names></name><name><surname>Xu</surname><given-names>HL</given-names></name></person-group><article-title>Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model</article-title><source>Colloids Surf B Biointerfaces</source><year>2017</year><volume>160</volume><fpage>704</fpage><lpage>14</lpage><comment>https://doi.org/10.1016/j.colsurfb.2017.10.029</comment><comment>PMid:29035818</comment><pub-id pub-id-type="pmid">29035818</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lima Fontes</surname><given-names>M</given-names></name><name><surname>Meneguin</surname><given-names>AB</given-names></name><name><surname>Tercjak</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>J</given-names></name><name><surname>Cury</surname><given-names>BSF</given-names></name><name><surname>Dos Santos</surname><given-names>AM</given-names></name><name><surname>Ribeiro</surname><given-names>SJL</given-names></name><name><surname>Barud</surname><given-names>HS</given-names></name></person-group><article-title>Effect of in situ modification of bacterial cellulose with carboxymethylcellulose on its nano/microstructure and methotrexate release properties</article-title><source>Carbohydr Polym</source><year>2018</year><volume>179</volume><fpage>126</fpage><lpage>34</lpage><comment>https://doi.org/10.1016/j.carbpol.2017.09.061</comment><comment>PMid:29111035</comment><pub-id pub-id-type="pmid">29111035</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panonnummal</surname><given-names>R</given-names></name><name><surname>Sabitha</surname><given-names>M</given-names></name></person-group><article-title>Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model</article-title><source>Int J Biol Macromol</source><year>2018</year><volume>110</volume><fpage>245</fpage><lpage>58</lpage><comment>https://doi.org/10.1016/j.ijbiomac.2017.10.112</comment><comment>PMid:29054520</comment><pub-id pub-id-type="pmid">29054520</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghate</surname><given-names>VM</given-names></name><name><surname>Kodoth</surname><given-names>AK</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Vishalakshi</surname><given-names>B</given-names></name><name><surname>Lewis</surname><given-names>SA</given-names></name></person-group><article-title>Colloidal nanostructured lipid carriers of pentoxifylline produced by microwave irradiation ameliorates imiquimod-induced psoriasis in mice</article-title><source>Colloids Surf B Biointerfaces</source><year>2019</year><volume>181</volume><fpage>389</fpage><lpage>99</lpage><comment>https://doi.org/10.1016/j.colsurfb.2019.05.074</comment><comment>PMid:31170645</comment><pub-id pub-id-type="pmid">31170645</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Bedi</surname><given-names>N</given-names></name></person-group><article-title>Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of Psoriasis</article-title><source>Pharm Nanotechnol</source><year>2018</year><volume>6</volume><issue>2</issue><fpage>133</fpage><lpage>43</lpage><comment>https://doi.org/10.2174/2211738506666180523112513</comment><comment>PMid:29788899</comment><pub-id pub-id-type="pmid">29788899</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meazza</surname><given-names>L</given-names></name><name><surname>Foster</surname><given-names>JA</given-names></name><name><surname>Fucke</surname><given-names>K</given-names></name><name><surname>Metrangolo</surname><given-names>P</given-names></name><name><surname>Resnati</surname><given-names>G</given-names></name><name><surname>Steed</surname><given-names>JW</given-names></name></person-group><article-title>Halogen-bonding-triggered supramolecular gel formation</article-title><source>Nat Chem</source><year>2013</year><volume>5</volume><issue>1</issue><fpage>42</fpage><lpage>7</lpage><comment>https://doi.org/10.1038/nchem.1496</comment><comment>PMid:23247176</comment><pub-id pub-id-type="pmid">23247176</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casal-Dujat</surname><given-names>L</given-names></name><name><surname>Griffiths</surname><given-names>PC</given-names></name><name><surname>Rodr&#x000ed;guez-Abreu</surname><given-names>C</given-names></name><name><surname>Solans</surname><given-names>C</given-names></name><name><surname>Rogerse</surname><given-names>S</given-names></name><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>L</given-names></name></person-group><article-title>Nanocarriers from dicationic bis-imidazolium amphiphiles and their interaction with anionic drugs</article-title><source>J Mater Chem B</source><year>2013</year><volume>38</volume><issue>1</issue><fpage>4963</fpage><lpage>71</lpage><comment>https://doi.org/10.1039/c3tb20289e</comment></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim&#x000f3;n</surname><given-names>D</given-names></name><name><surname>Jim&#x000e9;nez-Newman</surname><given-names>C</given-names></name><name><surname>Rodrigues</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Campo</surname><given-names>A</given-names></name><name><surname>Amabilino</surname><given-names>DB</given-names></name><name><surname>Calpena</surname><given-names>AC</given-names></name><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>L</given-names></name></person-group><article-title>Cationic Supramolecular Hydrogels for Overcoming the Skin Barrier in Drug Delivery</article-title><source>ChemistryOpen</source><year>2017</year><volume>6</volume><issue>4</issue><fpage>585</fpage><lpage>98</lpage><comment>https://doi.org/10.1002/open.201700040</comment><comment>PMid:28794954 PMCid:PMC5542755</comment><pub-id pub-id-type="pmid">28794954</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim&#x000f3;n</surname><given-names>D</given-names></name><name><surname>Tall&#x000f3;Dom&#x000ed;nguez</surname><given-names>K</given-names></name><name><surname>Gardu&#x000f1;o-Ram&#x000ed;rez</surname><given-names>ML</given-names></name><name><surname>Andrade</surname><given-names>B</given-names></name><name><surname>Calpena</surname><given-names>AC</given-names></name><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>L</given-names></name></person-group><article-title>Nanostructured supramolecular hydrogels:Towards the topical treatment of Psoriasis and other skin diseases</article-title><source>Colloids Surf B Biointerfaces</source><year>2019</year><volume>181</volume><fpage>657</fpage><lpage>70</lpage><comment>https://doi.org/10.1016/j.colsurfb.2019.06.018</comment><comment>PMid:31212138</comment><pub-id pub-id-type="pmid">31212138</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capezzera</surname><given-names>R</given-names></name><name><surname>Sala</surname><given-names>R</given-names></name><name><surname>Venturini</surname><given-names>M</given-names></name><name><surname>Zane</surname><given-names>C</given-names></name><name><surname>Calzavara-Pinton</surname><given-names>P</given-names></name></person-group><article-title>PUVA photochemotherapy:update 2003</article-title><source>G Ital Dermatol Venereol</source><year>2004</year><volume>139</volume><issue>2</issue><fpage>111</fpage><lpage>30</lpage></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>CA</given-names></name><name><surname>Gouv&#x000ea;a</surname><given-names>MM</given-names></name><name><surname>Antunes</surname><given-names>GR</given-names></name><name><surname>Freitas</surname><given-names>ZMF</given-names></name><name><surname>Marques</surname><given-names>FFC</given-names></name><name><surname>Ricci-Junior</surname><given-names>E</given-names></name></person-group><article-title>Nanoemulsion containing 8-methoxypsoralen for topical treatment of dermatoses:Development, characterization and ex vivo permeation in porcine skin</article-title><source>Int J Pharm</source><year>2018</year><volume>547</volume><issue>1-2</issue><fpage>1</fpage><lpage>9</lpage><comment>https://doi.org/10.1016/j.ijpharm.2018.05.053</comment><comment>PMid:29800737</comment><pub-id pub-id-type="pmid">29800737</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barradas</surname><given-names>TN</given-names></name><name><surname>Senna</surname><given-names>JP</given-names></name><name><surname>Cardoso</surname><given-names>SA</given-names></name><name><surname>de Holanda</surname><given-names>E</given-names></name><name><surname>Silva</surname><given-names>KG</given-names></name><name><surname>Elias Mansur</surname><given-names>CR</given-names></name></person-group><article-title>Formulation characterization and in vitro drug release of hydrogel-thickened nanoemulsions for topical delivery of 8-methoxypsoralen</article-title><source>Mater Sci Eng C Mater Biol Appl</source><year>2018</year><volume>92</volume><fpage>245</fpage><lpage>253</lpage><comment>https://doi.org/10.1016/j.msec.2018.06.049</comment><comment>PMid:30184748</comment><pub-id pub-id-type="pmid">30184748</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torsekar</surname><given-names>R</given-names></name><name><surname>Gautam</surname><given-names>MM</given-names></name></person-group><article-title>Topical Therapies in Psoriasis</article-title><source>Indian Dermatol Online J</source><year>2017</year><volume>8</volume><issue>4</issue><fpage>235</fpage><lpage>245</lpage><comment>https://doi.org/10.4103/2229-5178.209622</comment><comment>PMid:28761838 PMCid:PMC5518573</comment><pub-id pub-id-type="pmid">28761838</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>PK</given-names></name><name><surname>Gorain</surname><given-names>B</given-names></name><name><surname>Choudhury</surname><given-names>H</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Kesharwani</surname><given-names>P</given-names></name></person-group><article-title>Dendrimer entrapped microsponge gel of dithranol for effective topical treatment</article-title><source>Heliyon</source><year>2019</year><volume>5</volume><issue>3</issue><fpage>e01343</fpage><comment>https://doi.org/10.1016/j.heliyon.2019e01343</comment><comment>PMid:30957038 PMCid:PMC6431737</comment><pub-id pub-id-type="pmid">30957038</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathe</surname><given-names>P</given-names></name><name><surname>Saka</surname><given-names>R</given-names></name><name><surname>Kommineni</surname><given-names>N</given-names></name><name><surname>Raza</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>W</given-names></name></person-group><article-title>Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model</article-title><source>Drug Dev Ind Pharm</source><year>2019</year><volume>45</volume><issue>5</issue><fpage>826</fpage><lpage>838</lpage><comment>https://doi.org/10.1080/03639045.2019.1576722</comment><comment>PMid:30764674</comment><pub-id pub-id-type="pmid">30764674</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>MD</given-names></name><name><surname>Cassano</surname><given-names>N</given-names></name><name><surname>Bellia</surname><given-names>G</given-names></name><name><surname>Vena</surname><given-names>GA</given-names></name></person-group><article-title>Cyclosporine regimens in plaque psoriasis:an overview with special emphasis on dose, duration, and old and new treatment approaches</article-title><source>ScientificWorldJournal</source><year>2013</year><volume>2013</volume><fpage>805705</fpage><comment>https://doi.org/10.1155/2013/805705</comment><comment>PMid:23983647 PMCid:PMC3745987</comment><pub-id pub-id-type="pmid">23983647</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walunj</surname><given-names>M</given-names></name><name><surname>Doppalapudi</surname><given-names>S</given-names></name><name><surname>Bulbake</surname><given-names>U</given-names></name><name><surname>Khan</surname><given-names>W</given-names></name></person-group><article-title>Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis</article-title><source>J Liposome Res</source><volume>2019</volume><fpage>1</fpage><lpage>12</lpage><comment>https://doi.org/10.1080/08982104.2019.1593449</comment><comment>PMid:30897993</comment></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benigni</surname><given-names>M</given-names></name><name><surname>Pescina</surname><given-names>S</given-names></name><name><surname>Grimaudo</surname><given-names>MA</given-names></name><name><surname>Padula</surname><given-names>C</given-names></name><name><surname>Santi</surname><given-names>P</given-names></name><name><surname>Nicoli</surname><given-names>S</given-names></name></person-group><article-title>Development of microemulsions of suitable viscosity for cyclosporine skin delivery</article-title><source>Int J Pharm</source><year>2018</year><volume>545</volume><issue>1-2</issue><fpage>197</fpage><lpage>205</lpage><comment>https://doi.org/10.1016/j.ijpharm.2018.04.049</comment><comment>PMid:29698819</comment><pub-id pub-id-type="pmid">29698819</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapteva</surname><given-names>M</given-names></name><name><surname>Santer</surname><given-names>V</given-names></name><name><surname>Mondon</surname><given-names>K</given-names></name><name><surname>Patmanidis</surname><given-names>I</given-names></name><name><surname>Chiriano</surname><given-names>G</given-names></name><name><surname>Scapozza</surname><given-names>L</given-names></name><name><surname>Gurny</surname><given-names>R</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>M</given-names></name><name><surname>Kalia</surname><given-names>YN</given-names></name></person-group><article-title>Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways</article-title><source>J Control Release</source><year>2014</year><volume>196</volume><fpage>9</fpage><lpage>18</lpage><comment>https://doi.org/10.1016/j.jconrel.2014.09.021</comment><comment>PMid:25278258</comment><pub-id pub-id-type="pmid">25278258</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollina</surname><given-names>U</given-names></name></person-group><article-title>The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis</article-title><source>Am J Clin Dermatol</source><year>2007</year><volume>8</volume><issue>3</issue><fpage>157</fpage><lpage>73</lpage><comment>https://doi.org/10.2165/00128071-200708030-00003</comment><comment>PMid:17492844</comment><pub-id pub-id-type="pmid">17492844</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapteva</surname><given-names>M</given-names></name><name><surname>Mondon</surname><given-names>K</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>M</given-names></name><name><surname>Gurny</surname><given-names>R</given-names></name><name><surname>Kalia</surname><given-names>YN</given-names></name></person-group><article-title>Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus:a targeted approach for the treatment of psoriasis</article-title><source>Mol Pharm</source><year>2014</year><volume>11</volume><issue>9</issue><fpage>2989</fpage><lpage>3001</lpage><comment>https://doi.org/10.1021/mp400639e</comment><comment>PMid:25057896</comment><pub-id pub-id-type="pmid">25057896</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>T</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Long</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus:permeability through psoriatic skin and antipsoriatic and antiproliferative activities</article-title><source>Int J Nanomedicine</source><year>2017</year><volume>12</volume><fpage>1485</fpage><lpage>1497</lpage><comment>https://doi.org/10.2147/IJN.S126210</comment><comment>PMid:28260894 PMCid:PMC5328661</comment><pub-id pub-id-type="pmid">28260894</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>T</given-names></name><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Tacrolimus nanoparticles based on chitosan combined with nicotinamide:enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose</article-title><source>Int J Nanomedicine</source><year>2017</year><volume>13</volume><fpage>129</fpage><lpage>142</lpage><comment>https://doi.org/10.2147/IJN.S150319</comment><comment>PMid:29317821 PMCid:PMC5743175</comment><pub-id pub-id-type="pmid">29317821</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolacott</surname><given-names>N</given-names></name><name><surname>Hawkins</surname><given-names>N</given-names></name><name><surname>Mason</surname><given-names>A</given-names></name><name><surname>Kainth</surname><given-names>A</given-names></name><name><surname>Khadjesari</surname><given-names>Z</given-names></name><name><surname>Vergel</surname><given-names>YB</given-names></name><name><surname>Misso</surname><given-names>K</given-names></name><name><surname>Light</surname><given-names>K</given-names></name><name><surname>Chalmers</surname><given-names>R</given-names></name><name><surname>Sculpher</surname><given-names>M</given-names></name><name><surname>Riemsma</surname><given-names>R</given-names></name></person-group><article-title>Etanercept and efalizumab for the treatment of psoriasis:a systematic review</article-title><source>Health Technol Assess</source><year>2006</year><volume>10</volume><issue>46</issue><fpage>1</fpage><lpage>233</lpage><comment>i-iv</comment><comment>https://doi.org/10.3310/hta10460</comment></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giulbudagian</surname><given-names>M</given-names></name><name><surname>Yealland</surname><given-names>G</given-names></name><name><surname>H&#x000f6;nzke</surname><given-names>S</given-names></name><name><surname>Edlich</surname><given-names>A</given-names></name><name><surname>Geisend&#x000f6;rfer</surname><given-names>B</given-names></name><name><surname>Kleuser</surname><given-names>B</given-names></name><name><surname>Hedtrich</surname><given-names>S</given-names></name><name><surname>Calder&#x000f3;n</surname><given-names>M</given-names></name></person-group><article-title>Breaking the Barrier - Potent Anti-Inflammatory Activity following Efficient Topical Delivery of Etanercept using Thermoresponsive Nanogels</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><issue>2</issue><fpage>450</fpage><lpage>63</lpage><comment>https://doi.org/10.7150/thno.21668</comment><comment>PMid:29290820 PMCid:PMC5743560</comment><pub-id pub-id-type="pmid">29290820</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerecke</surname><given-names>C</given-names></name><name><surname>Edlich</surname><given-names>A</given-names></name><name><surname>Giulbudagian</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Said</surname><given-names>A</given-names></name><name><surname>Yealland</surname><given-names>G</given-names></name><name><surname>Lohan</surname><given-names>SB</given-names></name><name><surname>Neumann</surname><given-names>F</given-names></name><name><surname>Meinke</surname><given-names>MC</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Calder&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Hedtrich</surname><given-names>S</given-names></name><name><surname>Sch&#x000e4;fer-Korting</surname><given-names>M</given-names></name><name><surname>Kleuser</surname><given-names>B</given-names></name></person-group><article-title>Biocompatibility and characterization of polyglycerol-based thermoresponsive nanogels designed as novel drug-delivery systems and their intracellular localization in keratinocytes</article-title><source>Nanotoxicology</source><year>2017</year><volume>11</volume><issue>2</issue><fpage>267</fpage><lpage>77</lpage><comment>https://doi.org/10.1080/17435390.2017.1292371</comment><comment>PMid:28165853</comment><pub-id pub-id-type="pmid">28165853</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ainbinder</surname><given-names>D</given-names></name><name><surname>Godin</surname><given-names>B</given-names></name><name><surname>Touitou</surname><given-names>E</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Dragicevic</surname><given-names>N</given-names></name><name><surname>Maibach</surname><given-names>HI</given-names></name></person-group><article-title>Ethosomes:Enhanced delivery of drugs to and across the skin</article-title><article-title>Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Nanocarriers</article-title><year>2016</year><publisher-loc>Berlin Heidelberg</publisher-loc><publisher-name>Springer</publisher-name><fpage>61</fpage><lpage>75</lpage><comment>https://doi.org/10.1007/978-3-662-47862-2_4</comment></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YT</given-names></name><name><surname>Shen</surname><given-names>LN</given-names></name><name><surname>Wu</surname><given-names>ZH</given-names></name><name><surname>Zhao</surname><given-names>JH</given-names></name><name><surname>Feng</surname><given-names>NP</given-names></name></person-group><article-title>Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy</article-title><source>Int J Pharm</source><year>2014</year><volume>471</volume><issue>1-2</issue><fpage>449</fpage><lpage>52</lpage><comment>https://doi.org/10.1016/j.ijpharm.2014.06.001</comment><comment>PMid:24907596</comment><pub-id pub-id-type="pmid">24907596</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>BJ</given-names></name><name><surname>Garg</surname><given-names>NK</given-names></name><name><surname>Beg</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Katare</surname><given-names>OP</given-names></name></person-group><article-title>Nanosized ethosomes-based hydrogel formulations of methoxsalen for enhanced topical delivery against vitiligo:formulation optimization, in vitro evaluation and preclinical assessment</article-title><source>J Drug Target</source><year>2016</year><volume>24</volume><issue>3</issue><fpage>233</fpage><lpage>246</lpage><comment>https://doi.org/10.3109/1061186X.2015.1070855</comment><comment>PMid:26267289</comment><pub-id pub-id-type="pmid">26267289</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartelds</surname><given-names>R</given-names></name><name><surname>Nematollahi</surname><given-names>MH</given-names></name><name><surname>Pols</surname><given-names>T</given-names></name><name><surname>Stuart</surname><given-names>MCA</given-names></name><name><surname>Pardakhty</surname><given-names>A</given-names></name><name><surname>Asadikaram</surname><given-names>G</given-names></name><name><surname>Poolman</surname><given-names>B</given-names></name></person-group><article-title>Niosomes, an alternative for liposomal delivery</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><issue>4</issue><fpage>e0194179</fpage><comment>https://doi.org/10.1371/journal.pone.0194179</comment><comment>PMid:29649223 PMCid:PMC5896898</comment><pub-id pub-id-type="pmid">29649223</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu Hashim II</surname><given-names>Abo</given-names></name><name><surname>El-Magd</surname><given-names>NF</given-names></name><name><surname>El-Sheakh</surname><given-names>AR</given-names></name><name><surname>Hamed</surname><given-names>MF</given-names></name><name><surname>Abd El-Gawad</surname><given-names>AEH</given-names></name></person-group><article-title>Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis:ex vivo-in vivo evaluation study</article-title><source>Int J Nanomedicine</source><year>2018</year><volume>13</volume><fpage>1059</fpage><lpage>79</lpage><comment>https://doi.org/10.2147/IJN.S156412</comment><comment>PMid:29503541 PMCid:PMC5824759</comment><pub-id pub-id-type="pmid">29503541</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassem</surname><given-names>AA</given-names></name><name><surname>Abd El-Alim</surname><given-names>SH</given-names></name><name><surname>Asfour</surname><given-names>MH</given-names></name></person-group><article-title>Enhancement of 8-methoxypsoralen topical delivery via nanosized niosomal vesicles:Formulation development, in vitro and in vivo evaluation of skin deposition</article-title><source>Int J Pharm</source><year>2017</year><volume>517</volume><issue>1-2</issue><fpage>256</fpage><lpage>268</lpage><comment>https://doi.org/10.1016/j.ijpharm.2016.12.018</comment><comment>PMid:27956194</comment><pub-id pub-id-type="pmid">27956194</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>MZ</given-names></name><name><surname>Mohammed</surname><given-names>AA</given-names></name><name><surname>Mokhtar Ibrahim</surname><given-names>M</given-names></name></person-group><article-title>Technology overview and drug delivery application of proniosome</article-title><source>Pharm Dev Technol</source><year>2017</year><volume>22</volume><issue>3</issue><fpage>302</fpage><lpage>11</lpage><comment>https://doi.org/10.3109/10837450.2015.1135344</comment><comment>PMid:26794727</comment><pub-id pub-id-type="pmid">26794727</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>V</given-names></name><name><surname>Chaurasia</surname><given-names>S</given-names></name></person-group><article-title>Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis</article-title><source>Mater Sci Eng C Mater Biol Appl</source><year>2017</year><volume>79</volume><fpage>168</fpage><lpage>176</lpage><comment>https://doi.org/10.1016/j.msec.2017.05.036</comment><comment>PMid:28629004</comment><pub-id pub-id-type="pmid">28629004</pub-id></element-citation></ref></ref-list></back></article>